Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 5, 2026, 4:41 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 81 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Transdermal estradiol patch Clear all
Not listed Phase 4 Interventional Accepts healthy volunteers

Kronos Early Estrogen Prevention Study (KEEPS)

NCT00154180
View directory record Official record
Conditions
Menopause, Arteriosclerosis
Interventions
Conjugated equine estrogens 0.45 mg/day, Transdermal estradiol, 50 mcg/day, Micronized progesterone, 200 mg/day x 12 d/month, CEE , progesterone, estradiol patch or placebo for each, CEE, progesterone, transdermal patch or the placebo
Drug
Lead sponsor
Kronos Longevity Research Institute
Other
Eligibility
42 Years to 58 Years · Female only
Enrollment
728 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2012
U.S. locations
9
States / cities
Phoenix, Arizona • San Francisco, California • New Haven, Connecticut + 6 more
Source: ClinicalTrials.gov public record
Updated Sep 13, 2009 · Synced Sep 5, 2026, 4:41 AM EDT
Terminated Phase 1 Interventional

Initiating Transdermal Estradiol Therapy in Turner's Syndrome

NCT00870220
View directory record Official record
Conditions
Turner's Syndrome
Interventions
Norditropin, Menostar 14mcg patch, Vivelle dot 25mcg patch
Drug
Lead sponsor
University of Chicago
Other
Eligibility
138 Months to 13 Years · Female only
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
3
States / cities
Chicago, Illinois • Baltimore, Maryland • Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Mar 10, 2014 · Synced Sep 5, 2026, 4:41 AM EDT
Completed Phase 2 Interventional Results available

Transdermal Estrogen in Older Premenopausal Women With Anorexia Nervosa

NCT02475265
View directory record Official record
Conditions
Anorexia Nervosa, Osteoporosis
Interventions
estradiol 0.045 mg/levonorgestrel 0.015mg
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
25 Years to 50 Years · Female only
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 21, 2019 · Synced Sep 5, 2026, 4:41 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

PARIS or PAtch RIng Study: A Trial to Evaluate NuvaRing Versus OrthoEvra

NCT00269620
View directory record Official record
Conditions
Contraception
Interventions
ethinyl estradiol/etonogestrel vaginal ring, ethinyl estradiol/norelgestromin transdermal contraceptive
Drug
Lead sponsor
University of Pittsburgh
Other
Eligibility
Female only
Enrollment
500 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2006
U.S. locations
10
States / cities
Los Angeles, California • Chicago, Illinois • Baltimore, Maryland + 7 more
Source: ClinicalTrials.gov public record
Updated Oct 20, 2008 · Synced Sep 5, 2026, 4:41 AM EDT
Recruiting Phase 4 Interventional

Ovarian Hormone Withdrawal, Anhedonia, and Reward Sensitivity in Women With Premenstrual Exacerbations of Depression

NCT06610305
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Transdermal estradiol, Progesterone, Transdermal placebo patch, placebo capsule
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 28, 2025 · Synced Sep 5, 2026, 4:41 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

Study Investigating the Efficacy and Safety of a Contraceptive Patch for 13 Cycles

NCT00910637
View directory record Official record
Conditions
Contraception
Interventions
Gestodene/EE Patch (BAY86-5016)
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years to 45 Years · Female only
Enrollment
1,502 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
63
States / cities
Birmingham, Alabama • Glendale, Arizona • Phoenix, Arizona + 54 more
Source: ClinicalTrials.gov public record
Updated Apr 7, 2021 · Synced Sep 5, 2026, 4:41 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Midlife Cholesterol Study

NCT00361075
View directory record Official record
Conditions
Menopause, Postmenopause, Premenopause, Cardiovascular Disease
Interventions
transdermal estradiol patch (Vivelle), oral estrogen (Estrace), progesterone (Prometrium)
Drug
Lead sponsor
Northwestern University
Other
Eligibility
47 Years to 55 Years · Female only
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1998 – 2005
U.S. locations
2
States / cities
Chicago, Illinois • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Nov 4, 2014 · Synced Sep 5, 2026, 4:41 AM EDT
Terminated Phase 4 Interventional Accepts healthy volunteers Results available

The Menopause Transition: Estrogen Variability, Stress Reactivity and Mood

NCT03003949
View directory record Official record
Conditions
Perimenopausal Disorder, Stress, Emotional
Interventions
Estradiol Patch, 0.1 Mg/24 Hours Weekly Transdermal Film, Extended Release, Placebo Patch, Progesterone Capsule, Placebo Oral Capsule
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
45 Years to 60 Years · Female only
Enrollment
82 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2020
U.S. locations
2
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 25, 2021 · Synced Sep 5, 2026, 4:41 AM EDT
Completed Early Phase 1 Interventional

Inpatient Adolescent Contraception

NCT04423068
View directory record Official record
Conditions
Pregnancy Related, Contraception, Contraceptive Usage, Contraception Behavior, Pregnancy
Interventions
SexHealth II, Contraceptive
Behavioral · Drug
Lead sponsor
Children's Mercy Hospital Kansas City
Other
Eligibility
14 Years to 21 Years · Female only
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated Apr 4, 2023 · Synced Sep 5, 2026, 4:41 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Study to Evaluate the Contraceptive Efficacy/Safety of a Low Dose EE/LNG Transdermal Contraceptive Delivery System

NCT01181479
View directory record Official record
Conditions
Contraception
Interventions
AG200-15 (cycles 1-13), Lessina crossover to AG200-15
Drug
Lead sponsor
Agile Therapeutics
Industry
Eligibility
17 Years to 40 Years · Female only
Enrollment
1,504 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2012
U.S. locations
80
States / cities
Huntsville, Alabama • Mobile, Alabama • Chandler, Arizona + 77 more
Source: ClinicalTrials.gov public record
Updated Jul 2, 2018 · Synced Sep 5, 2026, 4:41 AM EDT
Completed Phase 2 Interventional

Neoadjuvant Estradiol or Androgen Deprivation in Clinically Localized Prostate Cancer

NCT00167648
View directory record Official record
Conditions
Cancer, Prostate Neoplasms
Interventions
Leuprolide or goserelin, Transdermal estradiol
Drug
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older · Male only
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
2
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jan 18, 2009 · Synced Sep 5, 2026, 4:41 AM EDT
Recruiting Phase 2 Interventional

Transdermal Estrogen in Women With Anorexia Nervosa

NCT03875378
View directory record Official record
Conditions
Anorexia Nervosa
Interventions
Transdermal estrogen, Placebos
Drug
Lead sponsor
Pouneh K. Fazeli, MD
Other
Eligibility
19 Years to 45 Years · Female only
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2028
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 17, 2026 · Synced Sep 5, 2026, 4:41 AM EDT
Completed Not applicable Interventional Results available

Comparison of Transdermal and Oral Estrogens in Adolescent Girls With Ovarian Failure

NCT01023178
View directory record Official record
Conditions
Ovarian Failure, Premature
Interventions
17beta Estradiol, Conjugated estrogens, 17Beta Estradiol - transdermal, Progesterone, micronized
Drug
Lead sponsor
Stanford University
Other
Eligibility
12 Years to 18 Years · Female only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Jan 19, 2017 · Synced Sep 5, 2026, 4:41 AM EDT
Completed Phase 4 Interventional

Efficacy and Safety Study in Postmenopausal Women to Determine the Lowest Effective Dose for Relief of Moderate to Severe Hot-Flushes

NCT00206622
View directory record Official record
Conditions
Hot Flashes
Interventions
Climara PRO (Estradiol / Levonorgestrel transdermal), Menostar (Estradiol transdermal), Placebo transdermal
Drug
Lead sponsor
Bayer
Industry
Eligibility
40 Years and older · Female only
Enrollment
425 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
45
States / cities
Huntsville, Alabama • Chandler, Arizona • Phoenix, Arizona + 38 more
Source: ClinicalTrials.gov public record
Updated May 28, 2009 · Synced Sep 5, 2026, 4:41 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Pharmacokinetic Evaluation of Bioidentical Compounded Estrogen Cream and Natural Progesterone

NCT00864214
View directory record Official record
Conditions
Menopause
Interventions
bioidentical hormone (Biest), bioidentical hormone (Vivelle-Dot)
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
40 Years to 60 Years · Female only
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2010
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 15, 2012 · Synced Sep 5, 2026, 4:41 AM EDT
Completed Phase 4 Interventional Results available

Raloxifene and Rimostil for Perimenopause-Related Depression

NCT00030147
View directory record Official record
Conditions
Perimenopausal Depression, Depression
Interventions
Raloxifene, Rimostil, Transdermal Estradiol, Placebo skin patch and placebo tablets
Drug
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
40 Years to 60 Years · Female only
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2015
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 4, 2016 · Synced Sep 5, 2026, 4:41 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Sex Hormones and Atherosclerosis Prevention in Perimenopausal Women

NCT00608062
View directory record Official record
Conditions
Arterial Stiffening, Aging, Menopause
Interventions
GnRHant - Ganirelix acetate, Transdermal estradiol patch, Transdermal placebo patch
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 70 Years · Female only
Enrollment
155 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2012
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Dec 23, 2020 · Synced Sep 5, 2026, 4:41 AM EDT
Active, not recruiting Phase 3 Interventional

Estrogen Administration for the Treatment of NASH in Postmenopausal Women

NCT04833140
View directory record Official record
Conditions
NASH - Nonalcoholic Steatohepatitis
Interventions
Estradiol patch, Placebo
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
45 Years to 70 Years · Female only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 6, 2026 · Synced Sep 5, 2026, 4:41 AM EDT
Withdrawn Phase 2 Interventional

Effects of an Estrogen Replacement Therapy Skin Patch on Ovulation in Women With Premature Ovarian Failure

NCT00370019
View directory record Official record
Conditions
Premature Ovarian Failure
Interventions
Estradiol/Medroxyprogesterone acetate
Drug
Lead sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
NIH
Eligibility
18 Years to 40 Years · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 1, 2017 · Synced Sep 5, 2026, 4:41 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Effects of Anorexia Nervosa on Peak Bone Mass

NCT01301183
View directory record Official record
Conditions
Anorexia Nervosa
Interventions
RhIGF-1 with transdermal 17-beta estradiol, Placebo and transdermal 17-beta estradiol
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
14 Years to 22 Years · Female only
Enrollment
75 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2020
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 12, 2021 · Synced Sep 5, 2026, 4:41 AM EDT
Not yet recruiting Phase 2 Interventional

Estrogen to Improve Quality of Life for Men With Newly Diagnosed or Recurrent Metastatic Hormone Sensitive Prostate Cancer, EQUIP Trial

NCT07466498
View directory record Official record
Conditions
Castration-Sensitive Prostate Adenocarcinoma, Metastatic Castration-Sensitive Prostate Adenocarcinoma, Stage IVB Prostate Cancer AJCC v8
Interventions
Androgen Receptor Pathway Inhibitor, Transdermal Estrogen, Bone Scan, Computed Tomography, Dual X-ray Absorptiometry, Gonadotropin-releasing Hormone Analog, Magnetic Resonance Imaging, Survey Administration, Biospecimen Collection
Drug · Procedure · Biological + 1 more
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Aug 30, 2026 · Synced Sep 5, 2026, 4:41 AM EDT
Recruiting Early Phase 1 Interventional Accepts healthy volunteers

Study to Assess Potential Impairments in Estradiol Augmentation of Gonadotropin Secretion in Polycystic Ovary Syndrome

NCT03401047
View directory record Official record
Conditions
Polycystic Ovary Syndrome
Interventions
Estradiol
Drug
Lead sponsor
University of Virginia
Other
Eligibility
18 Years to 30 Years · Female only
Enrollment
37 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2025
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Aug 4, 2025 · Synced Sep 5, 2026, 4:41 AM EDT
Terminated Phase 2 Interventional

Neurocognitive Mechanisms of Perimenstrual Estrogen Effects on Suicidality

NCT06191289
View directory record Official record
Conditions
Suicide
Interventions
Transdermal Estradiol, Placebo
Drug · Other
Lead sponsor
University of Illinois at Chicago
Other
Eligibility
20 Years to 40 Years · Female only
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Oct 28, 2025 · Synced Sep 5, 2026, 4:41 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Transgender Estradiol Affirming Therapy

NCT05010707
View directory record Official record
Conditions
Transgenderism
Interventions
Transdermal patch, Pro-thrombotic markers, Metabolic markers, Hormone Profile, Daily Sublingual Tablet, BID Sublingual Tablet, Spironolactone
Drug · Diagnostic Test
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 30 Years · Male only
Enrollment
39 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2024
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Nov 25, 2024 · Synced Sep 5, 2026, 4:41 AM EDT